Ascend Laboratories
- Company typePrivate
- Founded2000
- HeadquartersParsippany, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Ascend Laboratories firmographics
Firmographics- Name
- Ascend Laboratories
- Legal name
- Ascend Laboratories
- Website
- https://ascendlaboratories.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Ascend Laboratories industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industries
- Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
Keywords
Where Ascend Laboratories is headquartered
LocationHeadquarters
- HQ city
- Parsippany
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Ascend Laboratories business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Generic Pharmaceutical Sales: Revenue generated from the sale of FDA-approved generic medications to healthcare providers, pharmacies, and distributors across the United States. The company offers prescription-only (Rx) products across 7 therapeutic categories.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Co-pay assistance programs available for select medications |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Ascend Laboratories product offering
Product offeringCore offering
Ascend Laboratories manufactures and sells 300+ FDA-approved generic prescription medications across 7 therapeutic categories, in dosage forms including tablets, capsules, creams, inhalation products, solutions, and suspensions. The company operates an end-to-end operation spanning in-house API manufacturing (acquired via Norac in 2016), FDA-cGMP compliant production, and distribution through U.S. pharmaceutical wholesale and pharmacy channels.
Product overview
Ascend Laboratories is a generic pharmaceutical company offering 300+ FDA-approved generic medications across 7 therapeutic categories. The product portfolio includes tablets, capsules, creams, inhalation products, solutions, and suspensions. Products are marketed under the company's proprietary label following FDA approvals, with patient assistance programs such as CoPay cards offered for select medications like Deferasirox Granules and Droxidopa Capsules.
Differentiator
Problem solved
Functional benefit
Products and services
- Amlodipine & Olmesartan Tablets Generic combination antihypertensive medication in tablet form, available in 5mg and 10mg dosage strengths, indicated for hypertension treatment.
- Amlodipine Besylate Tablets Generic calcium channel blocker for hypertension treatment, available in 2.5mg, 5mg, and 10mg dosage strengths.
- Aripiprazole Tablets Generic antipsychotic medication in tablet form, available in multiple dosage strengths including 2mg, 5mg, 10mg, 15mg, 20mg, and 30mg.
- Atorvastatin Tablets Generic HMG-CoA reductase inhibitor (statin) for cholesterol management, available in 10mg, 20mg, 40mg, and 80mg dosage strengths.
- Azathioprine Tablets Generic immunosuppressant medication in tablet form, 50mg dosage strength.
- Cefdinir Capsules Generic antibiotic in capsule form, available in 300mg, 125mg, and 250mg dosage strengths.
- Cefprozil Tablets Generic antibiotic in tablet form, available in 251mg and 250mg dosage strengths.
- Deferasirox Granules Generic iron chelator for treating iron overload, offered with a CoPay assistance card to support patient out-of-pocket costs.
- Droxidopa Capsules Generic medication indicated for orthostatic hypotension, offered with a CoPay assistance card to reduce patient costs.
- 2026 Generic Medications Portfolio Expansion Portfolio expansion of 15 new FDA-approved generic medications added to Ascend's U.S. product line in May 2026, raising the total SKU count above 300.
Quantifiable outcome
- 300+ FDA-approved generic medications available
- +1 more outcomes
Companies that use Ascend Laboratories
Customer profileSegments2 records
Ideal customer profiles2 records
Ascend Laboratories technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Ascend Laboratories partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AlkemcoreIn 2010, Ascend Labs formed a strategic partnership with Alkem, an Indian pharmaceutical company. This partnership led to Ascend becoming Alkem's U.S. subsidiary in 2012, establishing Ascend as the U.S. presence for Alkem's pharmaceutical products. The partnership enabled Ascend to expand its generic pharmaceutical portfolio and leverage Alkem's product development capabilities.
Scale indicators6 records
Recent moves8 records
Expansion highlights4 records
Ascend Laboratories competitors and assessment
Company assessmentDirect peers
- Aurobindo Pharma USA: Aurobindo's US subsidiary is one of the largest Indian-affiliated generic manufacturers serving the US market with a similarly broad FDA-approved generic portfolio across multiple therapeutic categories and dosage forms. Direct comparable on model, parent backing, and US distribution strategy.
- Lupin Pharmaceuticals: Lupin is an India-headquartered generic drug maker with a major US commercial operation, offering FDA-approved generics across oral solids, injectables, and inhalation — directly comparable in product mix, regulatory posture, and strategic use of US subsidiaries to access the US market.
- Zydus Pharmaceuticals (USA): Zydus' US arm manufactures and distributes generic pharmaceuticals across therapeutic categories from India-parented operations, mirroring Ascend's positioning as an Indian-parent US generics subsidiary with FDA-approved SKUs and Broad therapeutic coverage.
- Dr. Reddy's Laboratories: Dr. Reddy's operates a large US generics business (including Promius Pharma) covering a broad portfolio of FDA-approved small-molecule generics and APIs — comparable on India-parented US generics strategy, vertical API integration, and broad therapeutic-category footprint.
- Glenmark Pharmaceuticals: Glenmark runs a US generics business with FDA-approved products across multiple therapeutic categories, comparable in distribution model (wholesaler-centric), target buyers, and reliance on parent-company pipeline feeding US operations.
- Amneal Pharmaceuticals: Amneal is a US-focused generic pharmaceutical manufacturer offering a broad portfolio of small-molecule generics across dosage forms and therapeutic categories, with vertically integrated manufacturing — directly comparable in scale, model, and channel relationships.
- Apotex Corp. Apotex is a major Canadian-based generic pharmaceutical company with substantial US operations, manufacturing and distributing FDA-approved generics across multiple therapeutic categories via wholesale and pharmacy channels.
Broad incumbents
- Teva Pharmaceutical Industries: Teva is the world's largest generic drug manufacturer with a massive US generics portfolio and well-established wholesale distribution — a broad incumbent that competes with Ascend across most of its therapeutic categories but at far greater scale and with branded specialty pharma alongside generics.
- Sandoz (Novartis): Sandoz is a global generics leader with a large US commercial presence (now independent of Novartis post-2023), offering broad FDA-approved generics across therapeutic categories. Larger and more diversified, but competes for the same wholesale-channel slots and pharmacy buyer relationships.
- Endo Pharmaceuticals: Endo operates a US generics business (Par Pharmaceutical) plus specialty branded products, competing in many of the same therapeutic categories as Ascend via the same wholesale distribution channels but at meaningfully larger scale.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Ascend Laboratories social profiles
Digital presenceAscend Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ascend Laboratories leadership team
Management profileNumber of profiles
Ascend Laboratories funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ascend Laboratories M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ascend Laboratories
What does Ascend Laboratories do?
Ascend Laboratories manufactures and sells 300+ FDA-approved generic prescription medications across 7 therapeutic categories, in dosage forms including tablets, capsules, creams, inhalation products, solutions, and suspensions. The company operates an end-to-end operation spanning in-house API manufacturing (acquired via Norac in 2016), FDA-cGMP compliant production, and distribution through U.S. pharmaceutical wholesale and pharmacy channels.
Is Ascend Laboratories a public or private company?
Ascend Laboratories is a private company. It is classified as corporate owned and is currently operating.
When was Ascend Laboratories founded?
Ascend Laboratories was founded in 2000. It employs 11 to 50 people.
Where is Ascend Laboratories based?
Ascend Laboratories is headquartered in Parsippany, United States, in the North America region.
How does Ascend Laboratories make money?
One revenue line is on record: generic Pharmaceutical Sales.
Who are Ascend Laboratories's main competitors?
Direct peers on record are Aurobindo Pharma USA, Lupin Pharmaceuticals, Zydus Pharmaceuticals (USA), Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Amneal Pharmaceuticals and Apotex Corp.. Broad incumbents are Teva Pharmaceutical Industries, Sandoz (Novartis) and Endo Pharmaceuticals.
Does Ascend Laboratories have an API?
No public API is recorded for Ascend Laboratories.
What industry is Ascend Laboratories in?
Ascend Laboratories's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAG, Generic APIs & Intermediates (Active Ingredients). Its NAICS code is 325412 and its SIC code is 2834.